● WEEKEND | NEXT OPEN: 2026-09-14 09:30 ET | 07:21 ET | PRICES DELAYED 15 MIN | NYSE · NASDAQ · TSX

Continuation From Yesterdays Post $CMPS 🍄

BULLISH by u/UnfairRazzmatazz987 | Sep 09, 2026 | 1↑ 1 comments | 1 views | VIEW ON REDDIT

$CMPS

$CMPS COMPASS PATHWAYS PLC - AMERICAN HEALTHCARE EQUITY SIMULATION

$14.08

-1.09 (-7.19%)

LAST PRICE · 15 MIN DELAY

DAY CHG -7.19%

5D CHG +6.42%

30D CHG +20.24%

AI SUMMARY — Compass Pathways released new 52-week topline data from their Phase 3 COMP005 trial showing additional benefit from another COMP360 dose in Part C, with extended durability out to 1 year. Key risks include regulatory approval uncertainty for psilocybin-based therapies and clinical trial setbacks.

TICKER	CMPS	USER	u/UnfairRazzmatazz987
RATING	BULLISH	ENTRY	$14.67
POSITION	676 sh SYN	BOOK VAL	$9918.86
CURRENT	$14.08	P&L %	-4.02%
CURR VAL	$9519.95	P&L $	-398.91

https://www.businesswire.com/news/home/20260909822109/en/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year